NKTR
Nektar TherapeuticsNASDAQHealthcare$76.99+1.69%ClosedMarket Cap: $1.56B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
16.88
P/S
27.46
EV/EBITDA
-13.42
DCF Value
$-29.19
FCF Yield
-13.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.6%
Operating Margin
-237.9%
Net Margin
-297.1%
ROE
-399.1%
ROA
-58.5%
ROIC
-53.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $21.8M | 100.0% | $-19.1M | $-36.1M | $-1.78 | — |
| FY 2025 | $55.2M | 100.0% | $-130.8M | $-164.1M | $-9.73 | — |
| Q3 2025 | $11.8M | 98.3% | $-31.5M | $-35.5M | $-1.87 | — |
| Q2 2025 | $11.2M | 100.0% | $-36.2M | $-41.6M | $-2.95 | — |
| Q1 2025 | $10.5M | 100.0% | $-44.5M | $-50.9M | $-3.62 | — |
| Q4 2024 | $29.2M | 72.7% | $14.3M | $7.3M | $0.51 | — |
| FY 2024 | $98.4M | 68.8% | $-105.2M | $-119.0M | $-8.68 | — |
| Q3 2024 | $24.1M | 81.6% | $-34.3M | $-37.1M | $-2.66 | — |
| Q2 2024 | $23.5M | 58.5% | $-49.8M | $-52.4M | $-3.76 | — |
| Q1 2024 | $21.6M | 60.6% | $-35.4M | $-36.8M | $-2.83 | — |
| Q4 2023 | $23.9M | 69.5% | $-33.5M | $-42.1M | $-3.30 | — |
| FY 2023 | $90.1M | 59.3% | $-137.4M | $-276.1M | $-21.79 | — |